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Abstract
Background. The tumor microenvironment plays a major tumor-supportive role in glioma. In particular, tumor-
associated macrophages (TAMs), which can make up to one-third of the tumor mass, actively support tumor 
growth, invasion, and angiogenesis. Predominantly alternatively activated (M2-polarized) TAMs are found in late-
stage glioma in both human and mouse tumors, as well as in relapse samples from patients. However, whether 
tumor-educated M2 TAMs can actively contribute to the emergence and growth of relapse is currently debated.
Methods. To investigate whether tumor-educated stromal cells remaining in the brain after surgical removal of 
the primary tumor can be long-lived and retain their tumor-supporting function, we developed a transplantation 
mouse model and performed lineage-tracing.
Results. We discovered that macrophages can survive transplantation and stay present in the tumor much longer 
than previously suggested, while sustaining an M2-polarized protumorigenic phenotype. Transplanted tumors 
showed a more aggressive growth and faster polarization of the TAMs toward an M2 phenotype compared with 
primary tumors, a process dependent on the presence of few cotransplanted macrophages.
Conclusions. Overall, we propose a new way for tumor-educated TAMs to contribute to glioma aggressiveness by 
long survival and stable protumorigenic features. These properties could have a relapse-supporting effect.
Key Points
 • A model for glioma transplantation was established to perform lineage-tracing in stromal 
cells.
 • Tumor-associated macrophages can be long-lived cells in the tumor microenvironment.
 • Transplanted tumors show more aggressive growth than primary tumors.











 Fuer user on 10 N
ovem
ber 2020
 2 Georgieva et al. Long-lived tumor-associated macrophages in glioma
Gliomas are the most common type of brain tumors with an 
incidence of 5 in 100 000 people1 and have been identified 
as an area of unmet clinical need. Glioblastoma represent 
the most abundant and aggressive type of glioma, charac-
terized by a diffuse infiltration into the brain parenchyma, re-
sistance to apoptosis, genomic instability, necrosis, hypoxia, 
and neovascularization.2 Despite maximal surgical resection 
followed by a combination of radiotherapy plus concom-
itant and adjuvant temozolomide chemotherapy, tumor 
recurrence is usually observed within 7  months and the 
median survival time is 14 months after diagnosis.3 Current 
therapeutic approaches target the tumor cells mainly with 
limited success due to a variety of reasons, such as the 
highly infiltrative growth pattern of the tumor, which makes 
complete resection challenging, radio- and chemoresistance 
of the tumor cells and intratumoral genetic heterogeneity.4,5
Besides the tumor cells, cells of the tumor microenvi-
ronment (TME) also strongly influence glioma growth. 
In particular, immune cells have recently emerged as 
a novel promising target for therapy.6 Yolk sac-derived 
tissue-resident brain macrophages (microglia), as well as 
bone-marrow-derived macrophages, infiltrating from the 
peripheral blood, are the most abundant immune cell type 
in glioma tissue. These tumor-associated microglia/macro-
phages (TAMs) are recruited to the tumor vicinity via sol-
uble factors, released from the tumor cells. TAMs comprise 
up to 30% of the tumor mass and their abundance correl-
ates with malignancy and tumor grade.7,8 Recent studies 
exploring TAMs as therapeutic targets presented contradic-
tory findings. While some demonstrated decrease in tumor 
size under reduction of TAM numbers,9–12 others showed 
increase in tumor size.13,14
Interestingly, TAMs can exhibit both tumor-suppressive 
and tumor-supportive functions depending on their acti-
vation state. Classically activated cytotoxic (also known as 
M1-type) TAMs mediate tumor resistance via the release of 
tumoricidal agents such as the proinflammatory cytokine 
tumor necrosis factor alpha. In contrast, alternatively ac-
tivated TAMs (M2-type) support tumor growth via matrix 
remodeling, phagocytic activity and the release of angio-
genic factors.7,15–18
M1-activated TAMs are abundant in early stages of tumor 
growth, which are often associated with chronic inflamma-
tion, whereas late-stage, aggressive tumors are populated 
with vast numbers of M2 TAMs. Latest research by us and 
others demonstrates that TAMs undergo a polarization 
switch from M1 to M2 during tumor progression and thus 
dynamically contribute to tumorigenesis.14,19 In surgically 
resected samples from patients, the number of M2 TAMs 
increased with glioma stage. Strikingly, samples from 
glioma relapse showed a similar density of M2 TAMs as 
high-grade glioma samples irrespective of the grade of the 
resected primary tumor.14
Despite best efforts and improved methods for com-
plete macroscopic surgical resection of the tumor, the 
peritumoral brain zone (PBZ) where 80%–90% of the re-
currences take place,20 often harbors tumor cells as well 
as other cellular and molecular components of the TME. 
Although most studies focus on residual tumor cells, it has 
been reported that nonresident macrophages can be found 
in the PBZ postsurgery as well.21 It is well established, that 
residual tumor cells can give rise to the recurrent tumor,22 
but whether and how remaining TAMs can support this 
process has not yet been addressed.
To address the question whether tumor-educated TAMs 
can contribute to a recurrent tumor growth, we developed 
a new transplantation mouse model and saw that TAMs 
can survive much longer than previously anticipated in 
the tumor context. With lineage-tracing experiments, we 
demonstrate that long-lived TAMs can keep a sustained M2 
polarization and a proangiogenic phenotype throughout 
tumor progression. Additionally, transplanted tumors con-
taining TAMs showed an earlier switch of macrophage po-
larization and a faster growth rate. Altogether, we propose 
that long-lived TAMs can actively support the aggressive-
ness of glioma relapse.
Materials and Methods
Animal Experiments
All animal experiments were performed in accordance 
with the Belgian law and EU regulations. Experimental 
procedures were approved by the Institutional Animal 
Care and Research Advisory Committee of the KU Leuven 
(P105/2012, P098/2016, and P205/2017). Animals were kept 
in standard housing conditions and received food and 
water ad libitum.
Mouse strains used were: C57BL/6, ROSAmTmG, and 
Cx3cr1GFP/Wt. Mice used for tumor implantations were 8–14 
weeks old. Both males and females were used for primary 
tumors. For tumor transplantations, only age-matched 
wild-type male mice were used.
Upon tumor implantation, animals were followed on a 
daily basis. Humane end-point was reached whenever the 
animal showed decreased mobility and hunched posture 
and/or had lost 20% of its body weight.
The target end-points were 2 and 4 weeks after tumor 
implantation. However, due to high variability of tumor 
growth between animals, many animals developed 
Importance of the Study
This study demonstrates for the first time that 
tumor-associated macrophages can be long-
lived cells in the context of glioma and contribute 
to tumor aggressiveness independently of their 
microenvironment. This survival benefit is linked 
to a stable tumor-promoting phenotype, sug-
gesting that macrophages have the capacity to 
contribute to glioma recurrence. These findings 
may be of clinical relevance for improving current 
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symptoms before the 4 weeks’ time point was reached, in 
which case they were sacrificed earlier. For simplicity, in 
this manuscript we refer to all animals, which reached a 
symptomatic end-point, as having “4 weeks” tumors.
Tumor Inoculations
Tumor inoculations were performed as described previ-
ously.14 A brief description can be found in Supplementary 
Material.
Tumor Piece Transplantations
For tumor transplantations, tumors were taken out and cut 
in small pieces with a scalpel and kept in DMEM complete 
until transplantation. Typically, pieces with a 250 µm diam-
eter with round edges were transplanted.
Immunofluorescence
Immunofluorescence staining was performed on 
free-floating 200  µm vibratome sections.23 A  detailed 
protocol and list of the antibodies used can be found in 
Supplementary Methods.
Tumor Size Measurement
Tumor volume was quantified using the Cavalieri’s prin-
ciple. In brief, the clearly delineated tumor area in every 
second 200 µm thick vibratome slice was measured using 
FIJI software and was multiplied by the number of slices 
and the thickness of each slice to calculate the total volume 
of the tumor.
Statistical Analysis
Statistical analysis was performed with GraphPad Prism 
7.02. Between-group comparisons were performed with 
Mann–Whitney U test or unpaired t test with or without 
Welch correction depending on the distribution of the data. 
For correlation analysis, Spearman’s rank correlation coef-
ficient was computed. A 2-tailed value of P < .05 was con-
sidered statistically significant.
Results
Macrophages Acquire an M2 Phenotype During 
Glioma Growth in Correlation With Increasing 
Tumor Size
We used a well-established syngeneic mouse glioma 
model that has the advantage of slow tumor growth, de-
velops progressive TME changes and vessel dysmorphia 
characteristics of different grades of human glioma14 and 
allows for longitudinal studies of tumor development. We 
implanted CT-2A24 glioma cell spheroids into the cortex 
of C57BL/6 mice as previously described14 and followed 
tumor growth. Mice were sacrificed at 2 weeks (early stage) 
or 4 weeks (late stage) of tumor growth, intracardially per-
fused and tumors were sectioned for immunofluorescence 
staining.
As observed previously within this mouse glioma 
model,14 after 2 weeks glioma growth a large number of 
major histocompatibility complex class II (MHCII)-positive 
(M1-polarized) macrophages is present in the tumor 
(Figure 1A), whereas the number of alternatively activated 
CD206-positive (MRC1 (mannose receptor); M2-polarized) 
macrophages is slightly lower. After 4 weeks of tumor 
growth, however, while the number of MHCII-positive 
macrophages remains unchanged, the number of CD206-
positive macrophages is significantly increased. In ad-
dition, the blood vessel network as identified by CD31 
(PECAM-1) staining appears more tortuous and chaotic 
with increased vessel diameter (Figure 1B).
Recent studies indicate that the M1/M2 dichotomy offers 
an oversimplified view of TAM polarization, since TAMs 
are a highly heterogeneous population and at any given 
point in a tumor, macrophages expressing a large variety 
of markers and receptors can be found.25 Nevertheless, 
when we assessed tumor size across different time points, 
CD206 expression (a marker for M2 polarization) strongly 
correlated with tumor size (Figure  1C, Spearman’s rank 
correlation coefficient: 0.78). The protumoral role of M2 
TAMs has been demonstrated convincingly in a large 
body of literature.7,15–18 Thus, determining MHCII expres-
sion vs CD206 expression as a description of M1/M2 po-
larization bears functional significance, allowing for a 
simplified but efficient way to distinguish between anti- 
and protumorigenic TAMs.
Altogether, macrophage populations dynamically change 
their polarization during glioma growth and the switch from 
M1 to M2 polarization is a good predictor of tumor size.
Tumor Transplantation Provides a Tool to Study 
Macrophage Survival
We previously reported that in human samples the number 
of M2 TAMs increase with increasing glioma grade and is 
strongly elevated in samples of tumor relapse.14 We hy-
pothesized that tumor-educated M2 macrophages which 
remain in the PBZ after surgical resection of the tumor 
may retain their protumorigenic properties. To investigate 
macrophage survival in the glioma context, we sought to 
lineage trace macrophages from primary into secondary 
tumor growth. In the absence of a suitable mouse re-
lapse model allowing for definitive lineage-tracing, we 
developed a transplantation model. Briefly, a tumor was 
grown for 2 or 4 weeks, taken out, cut in pieces and trans-
planted into brains of naïve mice (Figure 2A). Transplanted 
secondary tumors were grown for 2 weeks and then pro-
cessed for immunostainings. We will refer to tumors 
grown after transplantation as secondary tumors to distin-
guish them from the primary tumors they originate from. 
On average, the piece of tumor used for transplantation 
had a diameter of 0.25 mm (V = 0.0082 mm3), whereas a 
fully grown primary or secondary tumor had a diameter of 
4.4 mm (V = 46 mm3) after 4 weeks (Figure 2B), thus ex-
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In order to confirm that different cell types are still 
present in the small tumor piece we are transplanting, we 
performed immunofluorescent staining of tumor pieces 
which would normally be used for transplantation. Apart 
from CT-2A-tumor cells identified by their stable expres-
sion of blue fluorescent protein, we also confirmed that 
M1-, M2-polarized macrophages and some CD31-positive 
vessel-like structures (Figure 2C) were still present.
Primary Tumors Influence the Growth of the 
Secondary Tumor
In transplanted secondary tumors (Figure 2D) we found 
that the macrophage polarization in the secondary tu-
mors, derived from 2 weeks primary tumors (total tumor 
growth 4 weeks: 2 weeks primary growth + 2 weeks 
secondary growth) looks similar to the primary tumors 
at 2 weeks—with a comparable number of M1- and 
M2-polarized macrophages. However, in secondary tu-
mors originating from 4 weeks primary tumors (4 weeks 
primary growth + 2 weeks secondary growth), signif-
icantly more M2 macrophages were present, similar to 
what is found in primary tumors after 4 weeks growth. 
Note that in both regimes the duration of secondary 
tumor growth is identical, 2 weeks. Therefore, it appears 
that the status of the primary tumor influences the mac-
rophage switch in the new host of the transplanted sec-
ondary tumor. This finding suggests a potential memory 
effect which is established in the primary tumor and 
transferred with transplantation.
The Faster Switch in Macrophage Polarization 
in the Secondary Tumors Is Mediated by the 
Transplanted TME
In order to understand further which cell type is respon-
sible for the faster TAM shift to M2 polarization in 4  +  2 
week tumors, we designed an experiment in which we 
transplanted only tumor cells. Tumor cells acquire genomic 
instability and accumulate mutations very rapidly,26 which 
could be responsible for the observed effects. To test this 
hypothesis, we grew primary tumors for 4 weeks, digested 
them enzymatically and selected the BFP+ tumor cells via 
flow cytometry sorting. Next, we created spheroids in 
hanging drops from either tumor cells only or the complete 
TME (which includes nonmalignant cells) as control and 
transplanted those spheroids into naïve mice (Figure 3A).
After 2 weeks of secondary tumor growth, tumors 
originating from tumor cells only had a similar macro-
































































Figure 1. TAMs switch from M1 to M2 polarization during tumor growth with increasing tumor size. (A) Immunofluorescent staining of sections at 2 
and 4 weeks of tumor growth. Scale bar: 100 µm; 50 µm z-stack. Quantification of M1- and M2-positive macrophages per field of view in 2 and 4 weeks 
tumors. N = 7 (2 weeks) and 7 tumors (4 weeks); 5 fields of view/tumor. ** P  < .01. (B) Blood vessel diameters in 2 and 4 weeks tumors. **P  < .01. (C) 
The number of M2 macrophages correlates with tumor size. Each dot represents 1 tumor, the red line indicates the linear relationship of tumor volume 
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tumors grown from the complete TME there were signifi-
cantly more M2 macrophages (Figure 3B). Thus, by trans-
planting only tumor cells we were able to reset the tumor 
to its initial state and could exclude a major role of the 
tumor cells for the faster macrophage polarization switch 
in the secondary tumors. However, we found no significant 
difference in the total number of macrophages as identi-
fied by F4/80 staining and in tumor size (Figure 3C and D).
Overall, these results suggest that potential changes in 
tumor cells that may occur during primary growth are not 
responsible for the faster macrophage switch in the sec-
ondary tumors.
TAMs Survive the Transplantation and Are 
M2-Polarized
Next, we sought to understand what type of cells survives 
the transplantation and could potentially influence the 
growth of the secondary tumor. In order to lineage trace 
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Figure 2. Transplantation model used in the study. The progression state of the primary tumor induces an earlier switch of TAM polarization in 
the secondary. (A) Schematic depicting the transplantation model. (B) Average size of the tumor piece used for transplantation in comparison with 
a full grown (4 weeks) tumor. (C) Immunofluorescent staining of 4 weeks tumor pieces typically used for transplantation (z-stack: 100 µm). Scale 
bar: 150 µm. (D) Immunofluorescent staining of sections of secondary tumor growth. Scale bar: 100 µm; 50 µm z-stack. Quantification of M1- and 
M2-positive macrophages in 2 + 2 and 4 + 2 weeks tumors. Data shown: mean + SEM. N = 8 (2 + 2 weeks) and 13 tumors (4 + 2 weeks); 5 fields of 

































































Figure 1. TAMs switch from M1 to M2 polarization during tumor growth with increasing tumor size. (A) Immunofluorescent staining of sections at 2 
and 4 weeks of tumor growth. Scale bar: 100 µm; 50 µm z-stack. Quantification of M1- and M2-positive macrophages per field of view in 2 and 4 weeks 
tumors. N = 7 (2 weeks) and 7 tumors (4 weeks); 5 fields of view/tumor. ** P  < .01. (B) Blood vessel diameters in 2 and 4 weeks tumors. **P  < .01. (C) 
The number of M2 macrophages correlates with tumor size. Each dot represents 1 tumor, the red line indicates the linear relationship of tumor volume 











 Fuer user on 10 N
ovem
ber 2020
 6 Georgieva et al. Long-lived tumor-associated macrophages in glioma
surviving cells, we grew primary tumors in ROSAmTmG 
mice, in which stromal cells express the Tomato fluores-
cent protein.27 Tumors were then transplanted in C57BL/6 
mice (Figure 4A). Tomato-positive cells were present in the 
transplanted tumors (Figure  4B), indicating that stromal 
cells can survive several weeks in the secondary tumors 
after transplantation. After counterstaining with an F4/80 
antibody, all Tomato-positive surviving cells were identi-
fied as F4/80+ macrophages (Figure 4C).
Since only F4/80+ macrophages survived the trans-
plantation, we switched to a macrophage-specific re-
porter mouse model for the primary tumors (Figure 4D). 
We used Cx3cr1GFP/Wt animals,28 in which one allele 
of the fractalkine receptor Cx3cr1 is replaced by green 
fluorescent protein knock-in. In this mouse model, both 
brain-resident macrophages (microglia) and infiltrating 
macrophages originating from the bone marrow have 
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Figure 3. The faster switch in macrophage polarization in the secondary tumors is mediated by the transplanted TME. (A) Schematic depicting 
the experimental approach. (B) Immunofluorescent staining of sections of 4 + 2 weeks tumor from complete TME and tumors from tumor cells only. 
Scale bar: 100 µm; 50 µm z-stack. Quantification of M1- and M2-positive macrophages. N = 10 (both groups); 5 fields of view/tumor. *P < .05. (C) 
Immunofluorescent staining and quantification of F4/80+ macrophages in 4 + 2 weeks tumor from complete TME and tumors from tumor cells only. 
Scale bar: 100 µm; 50 µm z-stack. N = 10 (complete TME) and 9 (tumor cells) tumors; 5 fields of view/tumor. (D) Tumor size of 4 + 2 weeks tumors from 
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Figure 4. TAMs survive the transplantations and are M2-polarized independently of tumor progression. (A) Schematic depicting the experimental 
approach for lineage-tracing of stromal cells. (B) Tomato+ (red) cells survive the transplantation and can be found in secondary tumors. Scale bar: 
300 µm; 50 µm z-stack. Right: magnification of boxed area, scale bar 100 µm. (C) Tomato+ surviving cells are F4/80+. Scale bar: 100 µm. N = 4 tumors. 
(D) Experimental approach for macrophage-specific lineage-tracing. (E) Cx3cr1-GFP+ surviving cells in the secondary tumor. Scale bar: 150 µm; 
50 µm z-stack. Right: magnification of boxed area, scale bar 50 µm. (F) Flow cytometry sort of surviving and host TAMs in a 4 + 4 weeks secondary 
tumor. N = 7 tumors. (G) Characterization of surviving TAMs in secondary tumors by immunofluorescent staining. Scale bar: 100 µm; 50 µm z-stack. 
****P < .0001 (H) Proliferation of surviving cells in transplanted tumors. Scale bar: 50 µm. Data shown: mean + SEM (F–H). Each dot represents 1 
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function.29 Indeed, after transplanting tumors originating 
from Cx3cr1GFP/Wt mice into C57BL/6 mice, we found 
GFP+ cells with a typical macrophage morphology in the 
secondary tumors (Figure 4E).
We quantified the number of surviving GFP+ cells per 
tumor via flow cytometry (Figure 4F). In large secondary 
tumors with an average of 15 000 000 total viable cells, we 
found an average of 561 824 F4/80high GFP− cells (macro-
phages, derived from the host mouse) and an average of 
only 115 F4/80high GFP+ cells (surviving macrophages, de-
rived from the donor mouse). Thus, the ratio of surviving 
to host-derived macrophages is 1:5000. For further immu-
nofluorescent analysis, we used an Alexa488-conjugated 
anti-GFP antibody to enhance the signal. The majority of 
surviving macrophages were M2-polarized (Figure  4G) 
and only a small percentage were M1-polarized. Some of 
the GFP+ surviving macrophages expressed the prolifer-
ation marker Ki67, indicating that they were proliferating, 
but overall the number of GFP+Ki67+ cells varied consider-
ably between tumors (Figure 4H).
Thus, a small number of TAMs can survive longer than 
previously anticipated (for weeks instead of days) in the 
tumor context and can sustain a M2 polarization.
Surviving Macrophages in Secondary Tumors Are 
More Protumorigenic Than Host Macrophages
In order to better understand the properties of surviving 
macrophages in secondary tumors, we compared them 
to host macrophages in the same tumors (Figure 5A). We 
analyzed secondary tumors from different time points 
(2 + 2, 4 + 2, and 4 + 4 weeks). At 2 + 2 weeks, 20.3% of 
GFP− F4/80+ cells are also CD206+ (M2-polarized), whereas 
the percentage of GFP+ F4/80+ CD206+ cells is significantly 
higher (86.9%). Similarly, in 4  +  2 weeks tumors, sig-
nificantly more of the GFP+ F4/80+ cells are also CD206+, 
compared with GFP− F4/80+ cells. However, at 4 + 4 weeks 
tumors, these differences are not present anymore. These 
results indicate that GFP+ surviving macrophages have a 
stable M2 polarization independently of the progression of 
the tumor or of the polarization of the majority of the host-
derived macrophages in the TME.
Since M2-polarized macrophages are known to relocate 
in the vicinity of blood vessels and contribute to blood 
vessel dysmorphia, we looked into whether surviving GFP+ 
macrophages would associate with the blood vessels in 
the tumor. Tumor blood vessels were identified by CD31 
staining and the distances from each macrophage to the 
nearest blood vessel were determined with the help of a 
customized Python script (for details, see Materials and 
methods). Consistently with the observations in Figure 5A, 
in 2 + 2 weeks secondary tumors GFP+ surviving cells are 
located significantly closer to the blood vessels in compar-
ison to their GFP− F4/80+ counterparts. A similar difference 
between surviving and host-derived TAMs is also observed 
in the 4 + 2 weeks secondary tumors. However, in 4 + 4 
weeks tumors there is no significant difference anymore 
between the distance to blood vessels of GFP+ surviving 
macrophages and GFP− host macrophages.
Overall, surviving TAMs in secondary tumors repre-
sent a unique population of TAMs in transplanted tumors, 
displaying a stable and TME-independent polarization 
status and associating with blood vessels.
Transplanted Secondary Tumors Are More 
Aggressive Compared With Primary Tumors
Since macrophages can survive the transplantation and 
have a protumorigenic phenotype, we next asked how 
this phenomenon would influence the overall properties 
of secondary tumors. We compared the growth rate of 
primary (4 weeks) and secondary (4 + 4 weeks) tumors. 
Typically, at the final stages of tumor growth, tumor-
bearing animals show signs of tumor burden such as 
reduced mobility and weight loss. Animals bearing sec-
ondary tumors started showing tumor-related symp-
toms significantly earlier than animals bearing primary 
tumors (Figure 6A, 19.3 days vs 22.8 days on average). 
Furthermore, animals bearing secondary tumors had 
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Figure 5. Characterization of host and surviving macrophages in secondary tumors. (A) M2 polarization in GFP− F4/80+ (all) and GFP+ F4/80+ (sur-
viving) TAMs in transplanted secondary tumors. N = 3–5 tumors/group. *P < .05, **P < .01. (B) Distance to closest blood vessel of GFP− F4/80+ (all) and 
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they became symptomatic (Figure  6B, 20.3% vs 3.7%) 
and they were bearing larger tumors (Figure  6C). This 
was also reflected in an increased number of TAMs 
(Figure  6D), but numbers of M2-polarized TAMs were 
not changed. In order to better understand the possible 
mechanism behind these observations we performed 
flow cytometry analysis of the T cell subsets in primary 
and transplanted tumors. We observed no difference in 
the percentage of total T cells as identified by CD45 and 
CD3 marker expression, however in transplanted tumors 
the percentage of cytotoxic CD8+ T cells was significantly 
decreased (Supplementary Figure S1), whereas there 
was a slight but significant increase in the percentage of 
CD4+ T cells. In both groups, approximately 30% of these 
lymphocytes were Tregs which were slightly (but not sig-
nificantly) higher in the transplanted tumors. These find-
ings suggest that a reduced T cell-mediated antitumor 
immunity and a possibly increased immune suppression 
were present in the transplanted tumors.
Altogether, secondary tumors display more aggressive 
growth than primary tumors.
Discussion
In a physiological context, tissue-resident macrophages 
can have different origins, such as embryonic yolk sac or 
liver, populate the target organ early in development30 
and create a relatively stable population, maintained 
through self-renewal or longevity.31,32 In contrast to ho-
meostatic conditions, in the context of inflammation and 
cancer, rapidly recruited bone-marrow-derived mono-
cytes give rise to infiltrating macrophages33 which are 
generally considered to be short-lived cells with a high 
turnover. During circulation in the blood, monocytes are 
particularly short-lived with a half-life of approximately 
2  days.31 After entering the tissue in an inflammatory 
context such as experimental autoimmune encephalitis 
or peritonitis, inflammatory macrophages have a strong 
but transient contribution to the inflammatory process 
and are removed upon resolution of inflammation,34,35 
mainly by local apoptosis.36 However, in the context of 
cancer the fate of infiltrating macrophages is particularly 
multifaceted and dynamic. A  lot of research has looked 
into macrophage recruitment into malignant sites, as 
well as TAM distribution and properties at different time 
points during tumor growth but little is known about 
what happens to TAMs in the long term within the tumor 
context or later on.
Here, we demonstrate that TAMs can survive for more 
than 6 weeks in the TME. In the used transplantation 
model, we found no evidence for other nonmalignant 
surviving cells, although CD31-positive endothelial cells 
were originally still present in the transplanted pieces. 
This is, to our knowledge, the first study to show that 
macrophages can be long-lived cells in a patholog-
ical context, and in a brain tumor model in particular. 
Moreover, TAMs are able to sustain their protumorigenic 
phenotype as M2-polarized cells, thus could potentially 
contribute to the emergence and aggressiveness of a 
relapse.
The role of TAMs in tumor recurrence has been a matter 
of intense research efforts. Following chemotherapy, 
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Figure 6. Secondary tumors display more aggressive growth than primary. (A) Days of primary and secondary tumor growth until symptoms of 
tumor burden are observed. N = 30 (4 weeks) and 25 (4 + 4 weeks) animals. ****P < .0001. (B) Percentage of body weight loss in mice bearing pri-
mary or secondary tumors as measured at humane end-point. **P < .01. (C) Tumor volume of primary and secondary tumors. **P < .01. (D) F4/80+ 
macrophages in primary and secondary tumors. *P < .05. (E) Number of M2 (CD206+) macrophages in primary and secondary tumors. Each dot rep-
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M2-polarized TAMs accumulate in perivascular areas and pro-
mote relapse.37 Bone-marrow-derived monocytes are actively 
recruited to the hypoxic tumor site after tumor irradiation, con-
tributing to the fast tumor recurrence38 and the postirradiation 
TME particularly favors M2 polarization.39 A recent Phase I/II 
clinical study showed that limiting macrophage recruitment 
to the irradiated site using an inhibitor of the SDF-1/CXCR4 
pathway is a promising approach for decreasing recurrence 
rates.40 The rate of accumulation of M2 TAMs in the primary 
tumor site post-treatment can be even used for early detection 
of relapse growth through molecular imaging.41
However, all the aforementioned studies focused ex-
clusively on newly recruited macrophages post-therapy. 
Here, we demonstrate that tumor-educated macro-
phages can survive for long periods of time and remain 
M2-polarized, thus the M2 polarization possibly confers 
a survival benefit. This observation is of high therapeutic 
relevance for several reasons. TAMs can be found in the 
PBZ in glioma patients postsurgery21 and are in part re-
sponsible for the resistance to treatment.42 In particular, 
M2-polarized macrophages are more resistant to irradia-
tion than M1 macrophages.43 Tumors coinjected with TAMs 
isolated from irradiated tumors show faster growth.16
M2 polarization of macrophages is induced by a ded-
icated set of cytokines such as IL4 and IL13, released 
by immune cells upon tissue damage or helminth in-
fection,44 and is crucial for limiting the potentially 
devastating effects of classical inflammation in mul-
tiple pathologies.45 During tumor progression, macro-
phages transition from predominantly M1-polarized to 
M2-polarized.46 However, the mechanisms driving this 
transition are currently not well understood. Previously, 
we showed by sequential labeling of TAMs being re-
cruited to the tumor, that in late-stage mouse gliomas, 
M2 polarization occurs shortly after infiltration from the 
blood in the local TME.14 This switch is probably driven 
by locally available cytokines, such as IL4. We are cur-
rently developing models which would enable us to ob-
serve the switch dynamically in an in vivo setting.
Strikingly, in early phases of transplanted secondary tu-
mors’ growth, surviving donor-derived macrophages dis-
play an M2 polarization, even though they are surrounded 
by M1-polarized host-derived macrophages, indicating 
that M2 donor-derived macrophages become insensitive 
to molecular cues in the local TME in contrast to host-
derived, newly recruited macrophages. Hence in those sur-
viving donor-derived macrophages the M2 polarization is 
stabilized, probably through epigenetic mechanisms.47,48 
How exactly the M2 polarization contributes to the lon-
gevity of these cells is an extremely interesting question, 
which remains to be addressed.
The ability of cancer cells to accumulate mutations 
during tumor progression has been postulated as a crucial 
enabling characteristic for tumor growth.49 Here, we dem-
onstrate that transplanted secondary tumors grow faster 
and are more aggressive than primary tumors, and that 
this effect is not due to intrinsic properties of the tumor 
cells, possibly due to the relative short time frame of our 
experiments which is insufficient for the tumor cells to ac-
quire a selective growth advantage. Since we observe that 
the only nonmalignant donor-derived cell type surviving in 
the secondary tumor were TAMs, the faster switch of M1 
to M2 and the increased aggressiveness of secondary tu-
mors is likely due to macrophage-driven mechanisms. 
This is particularly striking considering that the ratio of sur-
viving (donor-derived) to newly recruited (host-derived) 
TAMs is only 1:5000. However, this ratio is observed at 
the final time point, whereas during transplantation the 
donor-derived TAMs prevail in numbers. In the early phase 
of tumor growth after transplantation M2-polarized tumor-
educated macrophages have the potential to reeducate 
newly recruited host-derived macrophages through re-
lease of molecular factors inducing M2 polarization. 
This becomes particularly evident when we compare the 
M2 polarization status and relocation close to the blood 
vessels in transplanted tumors after 2 and after 4 weeks 
growth. After 2 weeks growth, the surviving TAMs have 
stronger protumorigenic properties than the host TAMs, 
but later on (at 4 weeks growth) these differences are lost. 
As the tumor grows, surviving TAMs reeducate newly re-
cruited host TAMs in an autocrine fashion, leading to an 
overall faster switch of TAMs to M2 and more aggressive 
tumors. Our analysis indicates that a reduced T cell-medi-
ated antitumor immunity was present in the transplanted 
tumors. Mechanistically, this less favorable immune micro-
environment could have contributed to an increased tumor 
aggressiveness in the transplanted tumors.
Future work will need to address the exact mechanism, 
by which long-lived macrophages can support tumor 
growth. For instance, what molecular factors are impor-
tant for reeducating newly recruited macrophages? Also, 
testing our observations in a relapse model in the mouse 
and specifically targeting long-lived macrophages post-
therapy to evaluate their contribution to a relapse occur-
rence would be of immense benefit for improving current 
therapeutic strategies. Stable labeling of TAMs in the PBZ 
of human patients during surgery and observing their lon-
gevity and phenotype over time would be extremely inter-
esting for developing new therapeutic strategies targeting 
glioma relapse.
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